Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.
University of Cincinnati study demonstrates that embedding addiction treatment into primary care residency training expands patient access and boosts physician confidence in treating SUDs.
State insurance regulators find Aetna, Anthem, Cigna, ConnectiCare, and UnitedHealthcare systematically underpaid mental health providers and restricted access to care.
Researchers create a new class of compounds that activate serotonin receptors linked to brain healing without causing hallucinations, potentially opening addiction treatment to broader populations.
MSDH becomes one of few state health departments offering direct clinic-based SUD care, using technology to identify risk earlier and reduce barriers.
New NIH-funded research shows oral GLP-1 drugs like orforglipron reach the central amygdala, opening potential pathways for treating substance use disorders.
Law enforcement reports fentanyl increasingly combined with xylazine, medetomidine, nitazenes and cychlorphine—substances that resist naloxone reversal.
First randomized double-blind study in Sweden finds psilocybin provides clinically meaningful depression relief within days, with 53% remission rate at six weeks.
Senate Bill 249 decriminalizes drug paraphernalia possession and expands sterile supply distribution, sparking disagreement over public safety and addiction treatment approaches.
UC San Francisco and Imperial College London researchers discover that one 25mg dose of psilocybin creates measurable anatomical brain changes lasting at least a month.